NCT04270838View on ClinicalTrials.gov

A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Rabies
Interventions
BIOLOGICAL

ChAdOx2 RabG

Single dose of ChAdOx2 RabG at different concentrations: 1x10\^10 and 5x10\^10

BIOLOGICAL

Inactivated Rabies Vaccine

A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units

Trial Locations (1)

Unknown

IHI Clinical Trial Facility, Bagamoyo

All Listed Sponsors
collaborator

Ifakara Health Institute

OTHER

lead

University of Oxford

OTHER